Inari Medical, Inc. (NASDAQ:NARI) Shares Bought by Fox Run Management L.L.C.

Fox Run Management L.L.C. raised its position in Inari Medical, Inc. (NASDAQ:NARI) by 97.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 15,826 shares of the company’s stock after acquiring an additional 7,830 shares during the period. Fox Run Management L.L.C.’s holdings in Inari Medical were worth $808,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. PNC Financial Services Group Inc. lifted its stake in shares of Inari Medical by 5.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,550 shares of the company’s stock worth $130,000 after acquiring an additional 128 shares during the period. Arizona State Retirement System increased its holdings in shares of Inari Medical by 0.9% in the 4th quarter. Arizona State Retirement System now owns 15,196 shares of the company’s stock valued at $776,000 after purchasing an additional 129 shares in the last quarter. Ieq Capital LLC increased its holdings in shares of Inari Medical by 0.3% in the 4th quarter. Ieq Capital LLC now owns 50,198 shares of the company’s stock valued at $2,563,000 after purchasing an additional 145 shares in the last quarter. HighTower Advisors LLC increased its holdings in shares of Inari Medical by 0.4% in the 4th quarter. HighTower Advisors LLC now owns 62,202 shares of the company’s stock valued at $3,175,000 after purchasing an additional 234 shares in the last quarter. Finally, Smartleaf Asset Management LLC increased its holdings in shares of Inari Medical by 128.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 634 shares of the company’s stock valued at $33,000 after purchasing an additional 356 shares in the last quarter. Institutional investors and hedge funds own 90.98% of the company’s stock.

Insiders Place Their Bets

In other Inari Medical news, Director William Hoffman sold 200,000 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $60.47, for a total transaction of $12,094,000.00. Following the sale, the director now directly owns 238,987 shares of the company’s stock, valued at $14,451,543.89. This trade represents a 45.56 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 10.60% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

NARI has been the subject of a number of research analyst reports. Baird R W downgraded shares of Inari Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 7th. Wells Fargo & Company reiterated an “equal weight” rating and issued a $80.00 price target (up previously from $65.00) on shares of Inari Medical in a report on Tuesday, January 7th. BTIG Research reiterated a “neutral” rating on shares of Inari Medical in a report on Wednesday, January 8th. William Blair reiterated a “market perform” rating on shares of Inari Medical in a report on Tuesday, January 7th. Finally, Robert W. Baird restated a “neutral” rating and set a $80.00 target price (down from $81.00) on shares of Inari Medical in a report on Tuesday, January 7th. Twelve research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $68.00.

Inari Medical Stock Performance

NASDAQ:NARI opened at $79.97 on Monday. Inari Medical, Inc. has a twelve month low of $36.73 and a twelve month high of $79.99. The company has a market capitalization of $4.68 billion, a P/E ratio of -59.24 and a beta of 1.02. The firm has a 50-day moving average price of $79.81 and a two-hundred day moving average price of $60.30.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.